key: cord-0271188-idew8hy6
authors: Singh, Bhoj Raj
title: Mitigating antimicrobial resistance with aspirin (acetylsalicylic acid) and paracetamol (acetaminophen): Conversion of doxycycline and minocycline resistant bacteria into sensitive in presence of aspirin and paracetamol
date: 2021-05-22
journal: bioRxiv
DOI: 10.1101/2021.05.21.445232
sha: 056a9d36935873fae47eb1321446c1c0df8c9592
doc_id: 271188
cord_uid: idew8hy6

The emergence of antimicrobial resistance (AMR) stimulated research for alternatives antimicrobials, repurposing of other drugs, antibiotic adjuvants and alternative therapies for infections. Antimicrobial activity of NSAIDs is often reported and this study evaluated the antimicrobial potential of the two most common NSAIDs, aspirin (acetylsalicylic acid) and paracetamol (acetaminophen), against 293 clinical strains of bacteria. The ability of aspirin and paracetamol to convert minocycline and doxycyclin-resistant bacteria into sensitivity was also tested using micro-broth dilution assays used for determining minimum inhibitory concentration (MIC). Aspirin inhibited all 293 bacterial strains at ≤10.24 mg/ mL concentration. Except for one strain each of Serratia grimaceae and S, aureus paracetamol inhibited none of the 293 strains at 10.24 mg/ mL. Of the 293 strains 116 (39.59%) were sensitive (MIC ≤4 μg/mL) to doxycycline and 127 (43.34%) to minocycline. Of the selected 57 minocycline-resistant (MIC >4 μg/mL) strains aspirin converted 32 (56.14%) to minocycline-sensitive. Of the 49 doxycycline-resistant (MIC >4 μg/mL) strains tested in presence of aspirin 30 (61.22%) turned sensitive. Of the 34 doxycycline-resistant strains tested in presence of paracetamol 11 (32.35%) become sensitive. The study concluded that most of the bacterial strains were not susceptible to aspirin and paracetamol at their concentrations often available in plasma at maximum therapeutic dose levels and had no significant change in their susceptibility to doxycycline and minocycline. The study indicated the potential of aspirin and its combination with antibiotics in the development of therapeutically useful topical antimicrobial formulations.

The global emergence of antimicrobial drug resistance (AMR) even against drugs of the 48 latest classes and generations of antibiotics is a mind-boggling problem for microbiologists and 49 clinicians. Several alternative therapies have been suggested and tried for mitigating the problem 50 of AMR. Scientists have also thought of "Drug repurposing" which is the use of the pre-existing 51 approved drugs for their antimicrobial or antibiotic adjuvant properties (1) . The synergism Of 164 strains 57 strains classified as minocycline-resistant (MIC >4 µg/mL) when tested 160 for minocycline MIC in presence of 1.28 mg/mL, 0.64 mg/mL, 0.32 mg/mL, 0.16 mg/mL, 0.08 161 8 mg/mL, 0.04 mg/mL,, 0.02 mg/mL, and 0.01 mg/mL aspirin 32, 28, 23, 20, 20, 11, 10 and 1 (E. However, after a higher therapeutic dose on intravenous administration plasma concentration of 230 paracetamol can be reached up to 30 µg/ mL. In supra-therapeutic toxic dosages plasma 231 concentration of paracetamol is reported even up to 1500 µg/ mL (24).

In the present study only 42 (14.33%) strains were sensitive to aspirin at ≤1 mg/ mL 233 concentration and none to paracetamol. Similarly, in an earlier study aspirin and paracetamol 234 failed to contain growth of Serratia, Bacillus and E. coli strains at 1 mg/ mL concentration (25).

Babik and coworkers (9) reported that aspirin failed to contain growth of E. coli and S. The study concluded that neither aspirin nor paracetamol have potential antibacterial 

Non-antibiotic pharmaceutical agents as antibiotic adjuvants

Drug repurposing for the treatment of 298 bacterial and fungal infections